manufactur issu facil fill/finish momenta gener
copaxon appear resolv clear way pend anda
potenti introduct could occur time would caus share
dilut like addit price pressur market mean momenta
could final help allevi cash burn
momenta announc result fda inspect mcpherson
plant contract fill/finish manufactur copaxon
classifi voluntari action indic vai statu mean
longer impedi fda grant drug approv facil
therefor momenta anda still pend approv
time momenta manag indic could market
vari implic compani first teva anticip
copaxon sale reach estim ww copaxon estim
revenu given believ current price discount roughli via
aggress introduct well take account current share
total prescript like continu steadi penetr current
assum teva copaxon sale erod y/i still
unknown time momenta introduct well unknown addit price
discount necessari achiev reason share continu believ
teva estim may prove accur therefor make chang time
howev look beyond simpli assum three competitor
eventu end price discount captur equal share would like lead
teva copaxon well momenta respect product level
roughli annual run rate teva would mean current
 copaxon sale estim would modestli high
overal implic teva expect cost reduct
manag recent announc like allow teva simpli tread water
current oper cash gener recal full year cash oper
guidanc reach roughli would note copaxon
essenti full year fairli reason assum potenti copaxon
degrad potenti impact revenu potenti proair gener
roughli divest revenu potenti concerta competit
oper cost reduct simpli keep teva current cash gener
posit best would assum increment cost reduct
moder improv situat copaxon like degrad even
current trade level publish enterpris valu roughli
mean teva trade roughli ebitda roughli lever
like gener cash flow view simpli expens
believ equiti could still suffer even level
pleas see page report import disclosur
current estim copaxon formul contribut roughli
sale arriv figur assum roughli copaxon
brand sale price discount well like share penetr
momenta/novarti more-likely-than-not near term approv
estim could prove high depend time launch
place pressur abl secur approv difficult
formul pipelin advair restasi neulasta
valuat current trade ebitda lower
teva still punish leverag continu view busi model
rel unimpress valuat fair discount interest
us sinc februari acquisit abbott establish product
well june acquisit august
acquisit meda adjust free cash flow net capit expenditur
continu tread roughli level see slide although shorter-
term investor encourag could near-term differenti product
win believ long-term investor cash gener trend troubl
caus paus analyz health underli busi fact like
gener manufactur caus question entir busi model
interestingli asid larger well-known acquisit detail
continu buy product although disclos quarterli file
mention press releas recent compani list
acquisit year-to-d total acquisit cost varieti mostli
undisclos asset commerci right find troubl nearli half
oper cash gener redeploy alreadi commerci asset
sale figur disclos
specif reiter continu expect gener
adjust free cash flow net capit expenditur level similar
record evidenc manag
slide built last present specif net cash provid oper
activ increas million billion year end decemb
compar billion year end decemb would note
epipen contribut roughli revenu declin
sever evidenc manag guidanc combin
acquisit last three year well new product launch
essenti off-set epipen declin well obviou eros base busi
global inclus least quarter copaxon contribut
help without attempt adjud everi put take busi
simpl analysi somewhat descript busi model entireti
bottom line type dynam expens acquisit simpli replac
eros comfort long-term investor like mask true dynam
underli busi
although acknowledg could near-term trade share potenti
new gener could approv advair restasi neulasta
like continu believ long-term investor better wealth creat
momenta depend time market given share split novarti even
product would substanti lower annual cash burn manag
last indic cash end provid year cash
valuat methodolog arriv fair valu util discount cash flow dcf
approach addit assum busi develop deriv price
risk includ grow competit dynam specialti pharmaceut space
abil manag execut extern growth success acquir
new strateg accret product abil grow organ keep product
pipelin robust potenti regulatori delay reject failur pipelin product
econom sensit self-pay product weaken consum demand domest
intern price pressur market product failur execut new
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock teva pharmaceut mylan lab secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc januari et dissemin januari et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
prohibit receipt and/or review research constitut agreement reproduc display modifi distribut transmit disclos other outsid organ
cowen trademark display report own cowen may use without prior written consent
cowen compani llc new york boston san francisco chicago cleveland atlanta
outperform stock expect achiev total posit return least next month
market perform stock expect total return fall paramet outperform under-perform next month
under-perform stock expect achiev total neg return least next month
cowen compani equiti research rate distribut
distribut ratings/invest bank servic ib
correspond outperform rate stock defin cowen compani llc equiti research rate definit correspond market perform defin cowen
compani llc equiti research rate definit correspond under-perform defin cowen compani llc equiti research rate definit cowen
compani equiti research rate distribut tabl includ compani equiti research rate current suspend debt secur follow cowen
credit research trade
note buy hold sell term cowen compani llc use rate system constru invest option rather rate term
use illustr compli finra regul
rate histori
power bluematrix
teva pharmaceut rate histori
power bluematrix
mylan lab rate histori
power bluematrix
legend price chart
ken senior analyst cover specialti
pharmaceut cowen
year health care bank equiti
maughan equiti research associ
specialti pharma join cowen
ph biochemistri
